SCI论文选刊投稿常见问题

尤嘉琮

天津医科大学

《中国肺癌杂志》

Thoracic Cancer

《天津医科大学学报》

Email: yyjjcc_nk@163.com

一个有趣的征婚启示

性别:女 大龄博士


工作单位: 某医大附属医院

嫁妆: 自带10篇SCI论文已接

受,可改夫君为第一作者!



核心期刊与SCI



2017年新入选科技核心目录期刊

2018年新入选中国科技核心期刊(中国科技论文统计源期刊) CODE 刊 U030 西安工程大学学报 北方水稻 V573 西部人居环境学刊 大数据 Q937 消化肿瘤杂志电子版 导航定位与授时 信息安全学报 S081 电力工程技术 职业卫生与应急救援 G835 发育医学电子杂志 中国CT和MRI杂志 G546 供用电 中国癌症防治杂志 Q940 中国医院用药评价与分析 护士进修杂志 G625 中国肿瘤外科杂志 内燃机工程 G576 中华神经创伤外科电子杂志 强激光与粒子束 Q950 沈阳大学学报自然科学版 中华眼科医学杂志电子版 G075 实验室研究与探索 首都公共卫生

表 11-2 2018 年新入选中国科技核心期刊(中国科技论文统计源期刊)(英文)目录

000E	刊名	CODE	刊名
1173 1219 1226 J075	CHINESE JOURNAL OF CHEMISTRY CHINESE JOURNAL OF POPULATION, RESOURCES AND ENVIRONMENT DEFENCE TECHNOLOGY ENGINEERING	1220 H039 Q716 Q707	FRONTIERS OF EARTH SCIENCE HORTICULTURAL PLANT JOURNAL MILITARY MEDICAL RESEARCH WORLD JOURNAL OF TRADITIONAL CHINESE
N092	FRICTION		MEDICINE

2017年被踢出科技核心目录的期刊

- 中国妇幼保健
- 成都中医药大学学报
- 贵州医药
- 国际耳鼻喉头颈外科杂志
- 国际流行病学传染病学杂志
- 国际生物医学工程杂志
- 国际遗传学杂志
- 齐鲁医学
- 上海护理
- 现代仪器与医疗
- 中国健康心理学杂志
- 中国实用眼科杂志

2017版北大中文核心目录 (肿瘤类)


- ◆ 中华肿瘤杂志 (北京)
- ◆ 中华放射肿瘤学杂志(北京)
- → 肿瘤 (上海)
- ◆ 中国癌症杂志(上海)
- ◆中国肿瘤临床(天津)
- ◆ 中国肺癌杂志(天津)
- → 中国肿瘤 (杭州)
- ◆ 临床肿瘤学杂志(南京)
- ◆ 中华肿瘤防治杂志(济南)

期刊收录状态查询




http://mjl.clarivate.com/

Web of Science网址




http://www.webofknowledge.com

JCR



Welcome to Journal Citation Reports

Search a journal title or select an option to get started



ALL(8968)

Go to Journal Profile		Journals By Rank		Categ	ories By Rank				
Master Search	Q.	Journ	nal Titles Ranked by						
Compare Journals		Com	pare Selected Jo	Customize Indicators					
			Full Journa	al Title	ISSN	Journal Impact Factor •	Citable Items	Cited Half-Life	Citir
View Title Changes	nges 🕕		CA-A CANCER S		0007- 9235	244.585	29	3.0	
Select Journals	4		NEW ENGLAND	IOUDNAL	0028-				
Select Categories	4	2	OF MEDICINE	JOURNAL	4793	79.258	326	8.5	
		3	LANCET		0140- 6736	53.254	302	8.9	
Select JCR Year	4		CHEMICAL REV	IEWS	0009- 2665	52.613	261	7.6	
Select Edition	5	5	Nature Reviews	Materials	2058- 8437	51.941	48	1.4	
SCIE SSCI Open Access		6	NATURE REVIEW	WS DRUG	1474- 1776	50.167	38	7.6	
Open Access Category Schema		7	JAMA-JOURNAL AMERICAN MED ASSOCIATION		0098- 7484	47.661	208	>10.0	
Web of Science		8	Nature Energy		2058- 7546	46.859	96	1.4	
JIF Quartile	4	9	NATURE REVIE	WS CANCER	1474- 175X	42.784	49	8.6	
Select Publisher	4	10	NATURE REVIEW	WS	1474- 1733	41.982	54	7.7	
Select Country/Region	4	11	NATURE		0028- 0836	41.577	836	>10.0	
Select Sound yntegion	`	12	NATURE REVIEW GENETICS	WS	1471- 0056	41.465	48	7.4	
Impact Factor Range		13	SCIENCE		0036- 8075	41.058	769	>10.0	

JCR Category(235)

Median Aggregate

Aggregate

ECONOMICS		Category	Edition	#Journals	Total Cites	Impact Factor	Impact Factor		Category	Edition	#Journals	Total Cites	Impact Factor*	Impact Factor
Social Color Soci	-							1	CELL & TISSUE	SCIE	24	118,181	3.560	4.421
MOLECULAR BIOLOGY SCIE 292 3,620,042 2.911 4.295 4.640 4.640 5 6.640	2		SCIE	30	9 491,9	77 0.704	0.852	2		SCIE	27	127 990	3 457	4.663
MATERIAL SCIENCE 285 3,451,166 1,952 4,640 4 ONCOLOGY SCIE 222 1,930,764 3,186 5 NEUROSCIENCES SCIE 261 2,346,351 3,047 4,015 5 PHARMACQLOGY & SCIE 261 1,571,408 2,481 3,148 7 FEATONIC SCIE 31 216,794 3,079 3,079 7 FEATONIC SCIE 260 1,636,325 1,820 2,723 8 FEATONIC SCIE 31 3,047 4,015 5 FEATONIC SCIE 252 538,270 0,972 1,296 5 FEATONIC SCIE 241 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,893,126 2,067 3,487 1,993,126 2,994 1,994,126 2,994 1,994,126 2,994 1,994,126 2,994 1,994,126 2,994,127 2,994,126 2,994,126 2,994,127 2,994,126 2,994,12	3	MOLECULAR BIOLOGY	SCIE	29	2 3,620,0	12 2.911	4.295							5.803
Second Color Scie 261 2,346,351 3.047 4.015 5 Pharmacology Scie 31 216,794 3.079 5 Pharmacology Scie 261 1,571,408 2.481 3.148 7 7 Farmacology Scie 31 216,794 3.079 7 Farmacology Scie 261 2,346,351 3.047 7 Farmacology Scie 32 2.067 3.050 3.	4	MATERIALS SCIENCE,	SCIE	28	5 3,451,1	66 1.952	4.640	4	ONCOLOGY	SCIE	222	_,		4.597
PHARMACY SCIE 261 1,571,408 2,481 3,148 7 8 8 8 637,004 3,079	5		SCIE	26	1 2 346 3	1 3 047	4 015	5	IMMUNOLOGY	SCIE	155	1,280,201	3.185	4.359
ROBINEERING SCIE 260 1,636,325 1820 2.723 8 ENDOCRINOLOGY & SCIE 2.346,351 3.047								6	RHEUMATOLOGY	SCIE	31	216,794	3.079	4.115
8 MATHEMATICS, APPLIED SCIE 252 538,270 0.972 1.296 2.346,351 3.047 3.467	5		SCIE	20	1,571,4	J6 2.461	3.146	7	GASTROENTEROLOGY & HEPATOLOGY	SCIE	80	637,006	3.050	4.684
SCIENCES SCIE 241 1,893,126 2,067 3,487 10 MATERIAL S CIENCE 33 318,421 3,026 2,021 1,000,001 1,00	7	ELECTRICAL & ELECTRONIC	SCIE	26	0 1,636,3	25 1.820	2.723	8		SCIE	143	995,781	3.047	4.174
SCIENCES SCIE 241 1,695,120 2.007 3.487 10 BIOMATÉRIALS SCIE 33 318,421 3.026	8	MATHEMATICS, APPLIED	SCIE	25	2 538,2	70 0.972	1.296	8	NEUROSCIENCES	SCIE	261	2,346,351	3.047	4.015
11 ONCOLOGY SCIE 222 1,930,764 3,186 4,597 1 1 1 1 1 1 1 1 1	9	SCIENCES	SCIE	24	1 1,893,1	26 2.067	3.487	10	MATERIALS SCIENCE, BIOMATERIALS	SCIE	33	318,421	3.026	4.446
11	10	EDUCATION & EDUCATIONAL RESEARCH	SSCI	23	346,6	05 1.336	1.546	11	NANOSCIENCE & NANOTECHNOLOGY	SCIE	92	1,579,360	2.934	6.195
PLANT SCIENCES SCIE 222 1,053,834 1,422 2.696 3 MANAGEMENT SSCI 209 707,571 1,869 2.636 4 SURGERY SCIE 200 1,206,535 1.811 2.519 5 CLINICAL NEUROLOGY SCIE 197 1,303,868 2.645 3.498 6 CELL BIOLOGY SCIE 190 2,134,559 3.306 5.803 7 GEOSCIENCES MULTIDISCIPLINARY SCIE 189 917,458 1.917 2.662 8 LINGUISTICS SSCI 181 147,229 0.832 1.151 9 PUBLIC ENVIRONMENTAL & SCIE 171 3,468,233 2.199 5.561 9 CHEMISTRY MULTIDISCIPLINARY SCIE 171 1,200,361 2.687 20 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 22 POLITICAL SCIENCE SSCI 169 231,207 1.231 1.534 23 ZOOLOGY SCIE 160 3,321,942 2.205 3.546 24 APPLIED OGY SCIE 158 1,125,475 2.015 3.281 26 EVICOMENTAL & SCIE 158 1,125,475 2.015 3.281 27 EVICOMENTAL & SCIE 199 1,597 2.068 10 PUBLIC SCIE 171 1,200,361 2.687 26 EVICOMENTAL & SCIE 158 1,125,475 2.015 3.281 27 EVICOMENTAL & SCIE 1 1936 2.582 27 EVICOMENTAL & SCIE 1 1936 2.582 28 EVERIMENTAL & SCIE 133 861,758 2.707 28 EVICOMENTAL & SCIE 33 226,941 2.866 14 MEDICINE, RESEARCH & SCIE 133 861,758 2.707 4 MEDICINE, RESEARCH & SCIE 133 861,758 2.707 4 MULTIDISCIPLINARY SCIE 33 281,937 2.702 5 EVICOMENTAL & SCIE 180 887,997 1.857 2.662 6 SCIE SUSTAINABLE SCIE 33 308,939 2.693 7 CRITICAL CARE SCIE 33 308,939 2.693 8 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 9 ENERGY & FUELS SCIE 171 1,200,361 2.687 10 ENERGY & FUELS SCIE 171 1,200,361 2.687 10 ENERGY & FUELS SCIE 171 1,200,361 2.687 12 CLINICAL NEUROLOGY SCIE 197 1,303,868 2.645 13 GERIATRICS & SCIE 133 361,758 14 MULTIDISCIPLINAR SCIE 133 361,758 17 CRITICAL CARE SCIE 133 361,758 18 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 18 GENETICS & HEREDITY	11		SCIE	22	2 1,930,7	3.186	4.597	12	BIOCHEMISTRY &	SCIE	292	3.620.042	2.911	4.295
14 SURGERY SCIE 200 1,206,535 1.811 2.519 15 CLINICAL NEUROLOGY SCIE 197 1,303,868 2.645 3.498 16 CELL BIOLOGY SCIE 199 1,7458 1.917 2.662 17 GEOSCIENCES SCIE 189 917,458 1.917 2.662 18 LINGUISTICS SSCI 181 147,229 0.832 1.151 1.514 0.000 0.0	11	PLANT SCIENCES	SCIE	22	2 1,053,8	34 1.422	2.696							
15 CLINICAL NEUROLOGY SCIE 197 1,303,868 2.645 3.498 14 EXPERIMENTAL SCIE 133 861,738 2.707 16 CELL BIOLOGY SCIE 190 2,134,559 3.306 5.803 14 NUTRITION & DIETETICS SCIE 81 539,528 2.707 17 MULTIDISCIPLINARY SCIE 189 917,458 1,917 2.662 180 147,229 0.832 1.151 19 ENVIRONMENTAL & SCIE 180 887,997 1.857 2.645 19 ENERGY & FUELS SCIE 171 1,200,361 2.687 3.953 2.00 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 2.00 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 2.00 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 2.00 GENETICS & HEREDITY SCIE 166 381,649 1.101 1.464 3.187,427 2.653 2.00 4.664 4.00 4.664 4.00 4.664 4.00 4.666 4.00 4.666 4.00 4.0	13	MANAGEMENT	SSCI	20	9 707,5	71 1.869	2.636	13	GERONTOLOGY	SCIE	53	226,941	2.866	3.327
16 CELL BIOLOGY SCIE 190 2,134,559 3,306 5,803 14 NUTRITION & DIETETICS SCIE 81 539,528 2.707 17 GEOSCIENCES NULTIDISCIPLINARY SCIE 189 917,458 1.917 2.662 181 147,229 0.832 1.151 18 LINGUISTICS SSCI 181 147,229 0.832 1.151 19 OCCUPATIONAL HEALTH SCIE 180 887,997 1.857 2.645 18 CELL BIOLOGY SCIE 171 3,468,233 2.199 5.561 180 2.104,0361 2.687 3.953 14 NUTRITION & DIETETICS SCIE 81 539,528 2.707 16 GREEN & SUSTAINABLE SCIE 33 308,939 2.693 17 CRITICAL CARE SCIE 33 308,939 2.693 18 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 19 ENERGY & FUELS SCIE 97 1,278,571 2.658 20 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 21 CHEMISTRY, PHYSICAL SCIE 146 3,187,427 2.653 22 POLITICAL SCIENCE SSCI 169 231,207 1.231 1.534 23 ZOOLOGY SCIE 166 381,649 1.101 1.464 24 BIOTECHNOLOGY & SCIE 160 1,321,942 2.205 3.546 25 ECOLOGY SCIE 158 1,125,475 2.015 3.281 26 EVIRONMENTAL & SCIE 59 440,558 2.604 27 PUBLIC SCIE 1	14	SURGERY	SCIE	20	0 1,206,5	35 1.811	2.519	14	MEDICINE, RESEARCH &	SCIE	133	861 758	2 707	3.035
17 GEOSCIENCES SCIE 189 917,458 1.917 2.662 18 LINGUISTICS SSCI 181 147,229 0.832 1.151 19 PUBLIC ENVIRONMENTAL & SCIE 180 887,997 1.857 2.645 18 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 2.658 20 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 2.290 2.205 3.546 MICROBIOLOGY SCIE 166 3.81,649 1.101 1.464 1.321 1.534 2.205 3.546 1.321,942 2.205 3.546 2.687 2.698 2.698 2.699	15	CLINICAL NEUROLOGY		19								,		
19 PUBLIC 180 887,997 1.857 2.645 180 887,997 1.857 2.645 180	16		SCIE	19	0 2,134,5	59 3.306	5.803	14		SCIE	81	539,528	2.707	3.608
19 PUBLIC ENVIRONMENTAL & SCIE 180 887,997 1.857 2.645 18 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 2.645 18 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 2.658 20 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 22 POLITICAL SCIENCE SSCI 169 231,207 1.231 1.534 23 ZOOLOGY SCIE 166 381,649 1.101 1.464 24 APPLIED MICROBIOLOGY SCIE 160 1,321,942 2.205 3.546 20 CHEMISTRY, MEDICINAL SCIE 59 499,437 2.631 23 PERIPHERAL VASCULAR SCIE 65 635,754 2.629 2.631 2.6								16	SCIENCE & TECHNOLOGY	SCIE	33	281,937	2.702	5.062
19 ENVIRONMENTAL & SCIE 180 887,997 1.857 2.645 20 CHEMISTRY SCIE 171 3,468,233 2.199 5.561 20 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 22 POLITICAL SCIENCE SSCI 169 231,207 1.231 1.534 23 ZOOLOGY SCIE 166 381,649 1.101 1.464 24 APPLIED MICROBIOLOGY SCIE 160 1,321,942 2.205 3.546 25 ECOLOGY SCIE 158 1,125,475 2.015 3.281 26 PUBLIC ENVIRONMENTAL & SSCI 156 466,429 1.597 2.068 OCCUPATIONAL HEALTH SCIE SCIE 159 440,558 2.604 26 PUBLIC ENVIRONMENTAL & SSCI 156 466,429 1.597 2.068 OCCUPATIONAL HEALTH SCIE 159 440,558 2.695 EDUCATIONAL SCIE 1 97 1,200,361 2.687 2.645 20 CHEMISTRY, PHYSICAL SCIE 146 3,187,427 2.653 20 CHEMISTRY, PHYSICAL SCIE 146 3,187,427 2.653 21 CLINICAL NEUROLOGY SCIE 197 1,303,868 2.645 22 CHEMISTRY, MEDICINAL SCIE 59 499,437 2.631 23 PERIPHERAL VASCULAR SCIE 65 635,754 2.629 24 INFECTIOUS DISEASES SCIE 88 548,091 2.616 25 RESPIRATORY SYSTEM SCIE 59 440,558 2.604 26 HEMATOLOGY SCIE 71 618,164 2.595	18		SSCI	18	1 147,2	29 0.832	1.151	47	CRITICAL CARE	COLE	22	200.020	2 602	4.025
18 GENETICS & HEREDITY SCIE 171 1,200,361 2.687	19	ENVIRONMENTAL &	SCIE	18	0 887,9	7 1.857	2.645		MEDICINE			,		4.835
20 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 2.199 3.501 2.687 3.953 2.199 3.501 2.687 3.953 2.199 3.501 2.687 3.953 2.199 3.501 2.687 3.953 2.199 3.953 2.199 3.953 2.199 3.953 2.199 3.953 2.199 3.951 2.0681 2.000		OCCUPATIONAL HEALTH										-11		3.953
20 GENETICS & HEREDITY SCIE 171 1,200,361 2.687 3.953 22 POLITICAL SCIENCE SSCI 169 231,207 1.231 1.534 23 ZOOLOGY SCIE 166 381,649 1.101 1.464 24 APPLIED MICROBIOLOGY SCIE 160 1,321,942 2.205 3.546 25 ECOLOGY SCIE 158 1,125,475 2.015 3.281 26 ENVIRONMENTAL & SSCI 156 466,429 1.597 2.068 OCCUPATIONAL HEALTH 2000 100 100 100 100 100 100 100 100 10	20	CHEMISTRY, MULTIDISCIPLINARY	SCIE	17	1 3,468,2	33 2.199	5.561							5.412
22 POLITICAL SCIENCE SSCI 169 231,207 1.231 1.534 1.534 23 ZOOLOGY SCIE 166 381,649 1.101 1.464 BIOTECHNOLOGY & SCIE 160 1,321,942 2.205 3.546 24 APPLIED MICROBIOLOGY SCIE 160 1,321,942 2.205 3.546 25 ECOLOGY SCIE 158 1,125,475 2.015 3.281 26 ENVIRONMENTAL & SCIE 59 499,437 2.631 27 ENVIRONMENTAL & SCIE 59 499,437 2.631 281 281 282 282 283 283 283 283 283 283 283 283	20		SCIE	17	1 1,200,3	31 2.687	3.953		,					5.403
23 ZOOLOGY SCIE 166 381,049 1.101 1.404 24 APPLIED APPLIED MICROBIOLOGY SCIE 160 1,321,942 2.205 3.546 25 ECOLOGY SCIE 158 1,125,475 2.015 3.281 26 ENVIRONMENTAL & SSCI 266,429 1.597 2.068 OCCUPATIONAL HEALTH 27 EDUCATIONAL SCIE 1 936 2.582	22	POLITICAL SCIENCE	SSCI	16	9 231,2	7 1.231	1.534							3.498
24 MICROBIOLOGY SCIE 160 1,321,942 2.203 3.340 25 ECOLOGY SCIE 158 1,125,475 2.015 3.281 26 PUBLIC, ENVIRONMENTAL & SSCI 156 466,429 1.597 2.068 OCCUPATIONAL HEALTH SSCI 156 466,429 1.597 2.068 OCCUPATIONAL HEALTH 27 EDUCATIONAL SCIE 1 936 2.582	23	ZOOLOGY	SCIE	16	6 381,6	1.101	1.464	22		SCIE	59	499,437	2.631	2.931
25 ECOLOGY SCIE 158 1,125,475 2.015 3.281 25 RESPIRATORY SYSTEM SCIE 59 440,558 2.604 26 PUBLIC, ENVIRONMENTAL & SSCI 156 466,429 1.597 2.068 OCCUPATIONAL HEALTH SSCIE 159 440,558 2.604 26 HEMATOLOGY SCIE 71 618,164 2.595 EDUCATIONAL SCIE 1 936 2.582	24	BIOTECHNOLOGY & APPLIED	SCIE	16	0 1,321,9	12 2.205	3.546				65	,		4.102
PUBLIC. 26 ENVIRONMENTAL & SSCI 156 466,429 1.597 2.068 CUPATIONAL HEALTH SSCI 71 618,164 2.595 EDUCATION & EDUCATION & SCIE 71 936 2.582		MICROBIOLOGY												3.582
27 EDUCATIONAL SCIE 1 936 2.582	25		SCIE	15	8 1,125,4	75 2.015	3.281					,		4.075
27 EDÜCATIONAL SCIE 1 936 2.582	26	PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH	SSCI	15	6 466,43	29 1.597	2.068	26		SCIE	71	618,164	2.595	4.528
27 IMMUNOLOGY SCIE 155 1,280,201 3.185 4.359 27 RESEARCH	27	IMMUNOLOGY	SCIE	15	5 1,280,2	3.185	4.359	27	EDUČATIONAL RESEARCH	SCIE	1	936	2.582	2.582

Oncology(222)

	Full Journal Title	Total Cites	Journal Impact Factor*	Citable Items
1	CA-A CANCER JOURNAL FOR CLINICIANS	28,839	244.585	29
2	NATURE REVIEWS CANCER	50,407	42.784	49
3	LANCET ONCOLOGY	44,961	36.418	168
4	JOURNAL OF CLINICAL ONCOLOGY	156,474	26.303	400
5	Nature Reviews Clinical Oncology	8,354	24.653	45
6	Cancer Discovery	11,896	24.373	83
7	CANCER CELL	35,217	22.844	106
8	JAMA Oncology	5,707	20.871	151
9	ANNALS OF ONCOLOGY	38,738	13.926	377
10	JNCI-Journal of the National Cancer Institute	37,933	11.238	133
11	Journal of Thoracic Oncology	15,010	10.336	173
12	CLINICAL CANCER RESEARCH	81,859	10.199	752
13	SEMINARS IN CANCER BIOLOGY	6,330	10.198	78
14	LEUKEMIA	25,265	10.023	262
15	NEURO-ONCOLOGY	10,930	9.384	154
16	Cancer Immunology Research	4,361	9.188	106
17	CANCER RESEARCH	139,291	9.130	632

RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING (128)


	Full Journal Title	Total Cites	Journal Impact Factor •	Citable Items
1	JACC-Cardiovascular Imaging	8,104	10.247	100
2	European Heart Journal- Cardiovascular Imaging	4,630	8.336	151
3	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING	14,983	7.704	224
4	RADIOLOGY	54,109	7.469	340
5	JOURNAL OF NUCLEAR MEDICINE	27,101	7.439	304
6	CLINICAL NUCLEAR MEDICINE	4,756	6.281	145
7	INVESTIGATIVE RADIOLOGY	6,486	6.224	96
8	Circulation- Cardiovascular Imaging	5,438	6.221	111
9	IEEE TRANSACTIONS ON MEDICAL IMAGING	17,837	6.131	227
10	ULTRASOUND IN OBSTETRICS & GYNECOLOGY	12,420	5.654	181
11	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS	46,595	5.554	363
12	JOURNAL OF CARDIOVA SCULAR MAGNETIC RESONANCE	4,918	5.457	105
13	NEUROIMAGE	92,719	5.426	823
14	MEDICAL IMAGE ANALYSIS	6,383	5.356	146
15	RADIOTHERAPY AND ONCOLOGY	17,184	4.942	297
16	HUMAN BRAIN MAPPING	20,334	4.927	421

Surgery

	Full Journal Title	ISSN	Total Cites	Journal Impact Factor*	Citable Items
1	ANNALS OF SURGERY	0003- 4932	48,932	9.203	299
2	JAMA Surgery	2168- 6254	4,515	8.498	133
3	JOURNAL OF HEART AND LUNG TRANSPLANTATION	1053- 2498	11,129	7.955	143
4	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY	0022- 3050	29,695	7.144	130
5	ENDOSCOPY	0013- 726X	10,186	6.629	107
6	AMERICAN JOURNAL OF TRANSPLANTATION	1600- 6135	23,460	6.493	303
7	AMERICAN JOURNAL OF SURGICAL PATHOLOGY	0147- 5185	20,873	5.878	179
8	BRITISH JOURNAL OF SURGERY	0007- 1323	22,899	5.433	204
9	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY	0022- 5223	27,492	4.880	289
10	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS	1072- 7515	16,326	4.767	206
11	JOURNAL OF BONE AND JOINT SURGERY- AMERICAN VOLUME	0021- 9355	46,966	4.583	300
12	NEUROSURGERY	0148- 396X	28,592	4.475	233
13	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY	0749- 8063	15,568	4.330	257
14	JOURNAL OF NEURO SURGERY	0022- 3085	34,563	4.319	404
15	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH	0009- 921X	40,313	4.091	238
16	TRANSDI ANTATION	0041-	24 731	3 060	401

Thoracic Cancer

- Medline, SCI, SCOPUS等收录
- 刊发周期: 6个月



国内其他肿瘤/胸外相关期刊

国内:

- Cancer Communications(Chinese Journal of Cancer)
- 3.822 中山肿瘤 BioMed Central
- Chinese Journal of Cancer Research 3.689 北大肿瘤
- Journal of Thoracic Disease 1.804 广州呼研所 AME
- <u>Translational Cancer Research</u> 1.2 AME
- Journal of Cancer Research and Therapeutics 0.842 山东省立
- Cancer Biology & Medicine 4.607 天津肿瘤医院
- Annals of Translational Medicine--- 广医附院 AME
- Translational Lung Cancer Research AME
- Annals of Cardiothoracic Surgery AME

国内其他肿瘤/胸外相关期刊

国内:

- <u>Precision Cancer Medicine</u> 复旦肿瘤医院 AME
- Precision Clinical Medicine 四川大学华西医院 OUP
- NPJ Precision Oncology 河南肿瘤医院(中美(河南)荷美尔肿瘤研究院) NPG
- Precision Radiation Oncology 山东肿瘤医院 Wiley
- <u>Video-Assisted Thoracic Surgery</u> 华西医院 AME
- Chinese Clinical Oncology 八一医院 AME
- Shanghai Chest 上海胸科医院 AME
- Mediastinum 上海胸科医院 AME


•

合理选择投稿期刊




选刊的出发点

A survey: Reasons for choosing a journal (n=5,513)



Ian Rowlandsand Dave Nicholas. New Journal Publishing Models: An international survey of Senior Researchers. A CIBER Report for the Publishers Association and International Association of STM Publishers. 2005

稿件评审流程



投稿前的准备

仔细阅读 "Guide for Authors"

- 1、认真阅读期刊的题名页,以了解刊名、简单的办刊宗旨、编辑委员会组成、编辑部成员、出版商及其联系地址等。
- 2、浏览目录(table of contents),以确定该刊物是否发表你研究领域的文章及发表的比例有多大。
- 3、注意栏目设置,确定拟投稿件的栏目。
- 4、看拟投栏目的文章, 了解撰写要求、格式以及编辑特点。

CANCER

WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ,

Go to Journal Table of Contents Go to Ulrich's

Titles

ISO: Cancer JCR Abbrev: CANCER-AM CANCER SOC

Categories

ONCOLOGY - SCIE

Languages

ENGLISH

24 Issues/Year:

Key In	dicators												
Year ▼	Total Cites <u>Graph</u>	Journal Impact Factor <u>Graph</u>	Impact Factor Without Journal Self Cites	5 Year Impact Factor <u>Graph</u>	Immediacy Index Graph	Citable Items Graph	Cited Half- Life Graph	Citing Half- Life <u>Graph</u>	Eigenfacto Score Graph	Article Influence Score Graph	% Articles in Citable Items Graph	Normalized Eigenfacto Graph	
2015	62,200	5.649	5.474	5.434	1.303	459	>10.0	6.7	0.08818	2.081	89.76	10.05	88.028

Journal of Cancer

ISSN: 1837-9664

IVYSPRING INT PUBL PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA AUSTRALIA

Go to Journal Table of Contents Go to Ulrich's

Titles

ISO: J. Cancer JCR Abbrev: J CANCER

Categories

ONCOLOGY - SCIE

Languages

ENGLISH

9 Issues/Year:

Open Access from 2010

Key Indicators Impact Factor Total Journal Without 5 Year Immediacy Citable Citing Eigenfacto Normalized Average Cites Impact Journal Impact Index Items Half-Half-Score Influence Articles Eigenfacto Percentile Factor Factor Graph Life Life Score in Citable Graph Graph Cites Graph Graph Graph Graph Items Graph Graph Graph 0.00423 0.48165

CANCER JOURNAL

ISSN: 1528-9117

LIPPINCOTT WILLIAMS & WILKINS TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Go to Journal Table of Contents Go to Ulrich's

ISO: Cancer J. JCR Abbrev: CANCER J

Categories

ONCOLOGY - SCIE

Languages


ENGLISH

6 Issues/Year

Key Indicators Impact Factor Total Journal Without 5 Year Immediacy Citable Cited Citing Eigenfacto Article Normalizec Average Journal Influence Articles Cites Impact Impact Index Items Half-Half-Score Eigenfacto Percentile in Citable Factor Factor Life Life Score Graph Cites Graph Graph Graph Graph Graph 0.00758 0.86423 2015 2,582 3.496 3.465 3.782 0.414 1.381 4.29 63.615

刊名 ISSN (JCR)

办刊宗旨



ABOUT NEJM

The New England Journal of Medicine (NEJM.org) is dedicated to bringing physicians the best research and key information at the intersection of biomedical science and clinical practice, and to presenting the information in an understandable and clinically useful format. A career companion for physicians, NEJM keeps practicing physicians informed on developments that are important to their patients and keeps them connected to both clinical science and the values of being a good physician.

mature medicine

Aims and scope of the journal

Original research articles published in *Nature Medicine* range from basic findings that have clear implications for disease pathogenesis and therapy to the earliest phases of human investigation. Aiming to keep Ph.D. and M.D. readers informed of a wide range of biomedical research findings, the journal publishes the latest advances in cancer biology, vascular biology, neuroscience, inflammatory disease, infectious disease and metabolic disorders, among other fields. Reviews, Perspectives and other commissioned content clarify and give context to these biomedical research advances, and the News section reports on the latest developments in drug research and development.

学科分类

Cancer

Genitourinary Disease




Transcriptome evaluation of the relation between bot cancer outcomes (pages 2240–2247)

Hematologic Malignancies

Neuro-Oncoloav

Hyun Kim, Ingrid Kalchman, María Santiago-Jiménez, Jo Gretchen Hermann, Kosj Yamoah, Mohammed Alshalalfi Ross, Edward M. Schaeffer, Elai Davicioni, Nicholas Erh Den

Version of Record online: 31 JAN 2017 | DOI: 10.1002/cr



In a genomic analysis of 477 prostatectomy specimens, i not body mass index, is associated with prostate cancer

Abstract | Article | PDF(529K) | References | Reques


Head and Neck Disease

Effect of postoperative radiotherapy on survival for and pT4aN0 laryngeal cancer: Analysis of the Nation 2248–2257)

Evan M. Graboyes, Kevin Y. Zhan, Elizabeth Garrett-May Sharma and Terry A. Day Version of Record online: 9 FEB 2017 | DOI: 10.1002/cnu.30300

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib (pages 2268–2273)

Preetesh Jain, Philip A. Thompson, Michael Keating, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Hagop Kantarjian, Jan A. Burger, Susan O'Brien and William G. Wierda Version of Record online: 7 FEB 2017 | DOI: 10.1002/cncr.30596



At nearly 4 years of follow-up, patients with chronic lymphocytic leukemia who progress and/or transform on ibrutinib therapy have poor outcomes. It is essential to delineate the pattern of mutations and dynamics of clonal evolution in patients who discontinue ibrutinib because of disease progression/transformation and to identify novel pathways for therapeutic targeting to improve their survival.


Abstract | Article | PDF(190K) | References | Request Permissions

Treatment trends for patients with brain metastases: Does practice reflect the data? (pages 2274–2282)

Kiri A. Sandler, Narek Shaverdian, Ryan R. Cook, Amar U. Kishan, Christopher R. King, Isaac Yang, Michael L. Steinberg and Percy Lee Version of Record online: 8 FEB 2017 | DOI: 10.1002/cncr.30607

- 5、某些期刊刊登文章的投稿和接收日期(submitted and accepted dates), 你可据此计算出文章的发表周期。
- 6、查找有无北美和欧洲以外国家作者撰写的文章。
- 7、有些期刊刊登出全年的<mark>出版计划</mark>, 你可依此拟订自己的投稿计划。
- 8、是否收<mark>版面费(Page charges)?如果论文被接收</mark>,自己的 经济能力能否支付该杂志的发表全部费用。

各刊处理效率差别很大!



速度与周期

Indian J Surg (May–June 2015) 77(3):200–205 DOI 10.1007/s12262-012-0761-8

ORIGINAL ARTICLE


DACH1 Expresison in Osteosarcoma and Its Relativith Proliferation and Angiogenesis

Peng Ren • Ming-zhi Gong • Zhi-yong Wang • Peng Zhang • Peng Chen • Wan-li Ma • Cheng-jun Zhou

Received: 25 June 2012 / Accepted: 20 September 2012 / Published online: 27 September 2012

C Association of Surgeons of India 2012

Science's actual publication model



期刊投稿的主要问题

cover letter

- Concise and clear, less than one page. 简短明了、重点突出, 最好不要超过一页;
- •What to include? 投稿信的基本内容:
- Article type 稿件的栏目类型;
- Significance of your research 文章内容的重要性本研究意义
- > Reviewers 推荐的审稿人或需回避的审稿人;
- Corresponding author contact details 通讯作者详细的联系地址、电话号码、传真号码、E-mail地址

An effective cover letter

Dear Dr Zhou,

Please find enclosed our manuscript entitled "Localized biphasic type malignant mesothelioma arising in the peritoneum: Report of a case", by Kohno et al., which we would like to submit for publication as a Case report in *Thoracic Cancer*.

Localized malignant mesothelioma is an uncommon circumscribed tumor of the serosal membrane with the microscopic appearance of diffuse malignant mesothelioma, but without any evidence of infiltration. ...

背景介绍

This report describes a rare case of localized malignant biphasic (mixed epithelioid and sarcomatoid) mesothelioma arising in the peritoneum. A 69-year-old male with a history of asbestos exposure, complaining of a painful mass of left chest wall, was found to have a tumor of left peritoneum on computed tomography (CT). The resected tumor was histologically consistent with a malignant mesothelioma with mixed epithelioid and sarcomatoid type and no distant metastasis. The diagnosis of localized malignant biphasic mesothelioma arising in the peritoneum was appropriate because there was no evidence of any other primary tumor.

本文新意

We believe our findings would appeal to a broad audience, such as the readership of Thoracic Cancer

对期刊读者群的 帮助

All authors have read and approved the manuscript. We hope that you find our study worthy of publication. Please address all correspondence to....



- 标记修改部分
- 逐条答复

SPECIFIC COMMENTS TO REVIEWERS

Dear Reviewer #1

Thank you for spending time reviewing our work. We appreciate that you have found our work suggestive and valuable.

Reviewer's comment

Suzuki et al. described an extremely rare collision tumor, consisting of the three different histology of the lung cancer. I am very interested in the pathogenesis of the collision tumor that is possibly associated with IPF in the background lung. It was suggested that the chronic inflammation due to IPF may be carcinogenic stimuli, but it cannot be proven. In my opinion, examination of the gene mutations known to be related to be lung cancer pathogenesis may give us useful information. I understand it is not able to detect gene mutations (for example, EGFR, K-Ras, ALK, ERBB2, ect.) precisely. Taken together, this case report is suggestive and valuable, which is worth to publish in Thoracic Cancer.

Response to Reviewer#1

Thank you for your comments about driver gene mutations. We added the result of EGFR mutation in the manuscript.

Dear Reviewer #2

Thank you for spending time reviewing our work. We have answered your comment according to your suggestion.

Reviewer's comment

The final part of Conclusions is improper and must be suppressed.

Response to Reviewer #2

Thank you for your comments. We deleted the final part of conclusion according to your comments.

Dear Reviewer #3

Thank you for spending time reviewing our work. We appreciate that you finding our work as very interesting. We revised our manuscript according to your comments.

Reviewer's comments and responses to Reviewer #3

1. Were other diagnostic procedures like colonoscopy, CT-abdomen etc. performed? What were the results? Please specify them in your case report.

Thank you for your comment. This patient underwent whole body FDG-PET, and did not undergo other specific diagnostic procedures. We added the words 'whole body' in front of the FDG-PET in the manuscript.

2. I assume that immunohistochemical analysis of the tumor subtypes was performed. Please name the results and – if possible – ad more pictures of your stainings.

Thank you for your comments. We did not perform immunohitochemical analysis. Because we believe that morphology is sufficient enough to make pathological diagnosis for three neoplastic components which were squamous cell carcinoma, invasive mucinous adenocarcinoma and invasive non-mucinous adenocarcinoma.

3. Were the histological specimen examined by a reference pathologist/reference laboratory? What were the results?



Answers to the reviewer 1

1. The authors take our comments to consideration? "Answer: This research was done almost three years ago, it's my negligence that have lost the figures of gel running and sequencing results because of my computer paralysis." It means the authors are not ready to publish the article until they could repair the computer?

Answer: Firstly, I will apologize my negligence. Then, the reviewer misunderstood my meaning. Here, I try to explain. I have done this research almost 3 years ago, and my computer was paralyzed during that time, unfortunately, the figures of gel running and sequencing results have lost. After that, I have bought a new computer, but I couldn't find the figures back.

I hope this will make it acceptable for publication and I look forward to hearing from you soon.

The corresponding author is: *****, Ph.D. Prof. **** is the corresponding author as listed in the manuscript. In order to facilitate communication, please send a copy of communication letter to this E-mail address: ****@qq.com.

教育部公布的(发表论文) 常见的7类学术不端行为(七宗罪!)

- 1. 抄袭、剽窃、侵吞他人学术成果
- 2. 篡改他人学术成果
- 3. 伪造或者篡改数据、文献, 捏造事实
- 4. 伪造注释
- 5. 未参加创作, 在他人学术成果上署名
- 6. 未经他人许可,不当使用他人署名
- 7. 其他学术不端行为

数据手术室



OK, easy now. Just a little nip here and there. We don't want it to look like it's had any work done.



If data is questioned:

- Investigation
- Data are seized
- Substantiate all data




伪造修改图片.







图片手术




复制电泳条带 复制对照

擦除与改造图片






免疫金染色的修饰




借花献佛


Previously published

Submitted figure










From the *Baltimore Sun*(2002)

Surge in retracted publications



RETRACTION

Post date 12 January 2006



Serious errors. Cloning researcher Woo Suk Hwang has said he will withdraw a landmark paper published in Science earlier this year because of errors but says the conclusions are valid.

Investig rs of two papers of tee repontical to ence the wang et oned bla mittee, to claiming at a sig nce feel refore re



Pushing forward. Hwang told a press conference that his team would produce new evidence that they had made stem cells from cloned human embryos.

to retract their paper. All of the authors of Hwang et al., 2004 (2) have agreed their paper.

Science regrets the time that the peer reviewers and others spent evaluating these papers as well as the time and resources that the scientific community may have spent trying to replicate these results.

Donald Kennedy Editor-in-Chief

Retraction Watch*

Retraction Watch

Tracking retractions as a window into the scientific process

 A blog that reports on retractions of scientific papers.

An informal repository for retractions.

Investigate how journals themselves deal with retractions.

A new record: Major publisher retracting more than 100 studies from cancer journal over fake peer reviews

with 6 comments


Springer is <u>retracting 107 papers</u> from one journal after discovering they had been accepted with fake peer reviews. Yes, 107.

To submit a fake review, someone (often the author of a paper) either makes up an outside expert to review the paper, or suggests a real researcher — and in both cases, provides a fake email address that comes back to someone who will invariably give the paper a glowing review. In this case, Springer, the publisher of *Tumor Biology* through 2016, told us that an investigation produced "clear evidence" the reviews were submitted under the names of real researchers with faked emails. Some

of the authors may have used a third-party editing service, w the reviews. The journal is now published by SAGE.

The retractions follow another sweep by the publisher last ye retracted 25 papers for compromised review and other issue With the latest bunch of retractions, the journal has now retrindexed by Clarivate Analytics' Web of Science, formerly part — 2.9 — ranked it 104th out of 213 oncology journals.

Here's more from Springer's official statement, out today:



Tumor Biology

前列消糖汤治疗激素前列腺癌的临床疗效观察







□ CAJViewer下数 不支持讯雷等下载工具。

免费订阅



齐齐龄尔医学院学报、 Journal of Qigihar University of Medicine. 编辑部邮箱。 2016年02期 [给本刊投稿]

【作者】 廖春贤;

[Author] LIAO Chun-xian; Uropoiesis Surgical Department, Shunde First People's Hospital, Foshan, Guangdong;

【机构】广东省佛山市斷德区第一人民医院泌尿外科;

【摘要】目的观察探讨应用前列消瘾汤治疗激素前列腺癌的临床疗效。方法选取我院2012年3月至2014年11月收纳 的98例激素前列腺癌患者,按随机分配原则分为观察组和对照组,各49例,观察组激素前列腺癌患者,在对照组基础治疗 上,加用前列消癌汤治疗,对照组激素前列腺癌患者,使用戈舍瑞林,口服醋酸甲地孕酮等常规西药治疗。以3个月为一个 存程,连续进行半年。观察两组患者临床疗效,在两组治疗过后采取SAS焦虑量表、生活质量自评量表对患者生存质量 及心理状态的变化进行评估分析。结果两组患者进行各自治疗后在生活质量自评量表中的心理领域、生理领域、环 境领域、社会领域均具有显著差异,观察组各项评分均显著高于对照组,具有统计学意义(P<0.05)。观察组与对照组治 疗后焦虑情绪评分差别不大,无明显差异,不具有统计学意义(P>0.05)。两组治疗后焦虑情绪评分有明显差异,具有统计 学意义(P<0.05)。观察组激素前列腺癌患者总有效率95.9%。对照组激素前列腺癌患者总有效率77.5%。观察组总有效 率比对照组高,有明显差异,具有统计学意义(P<0.05)。结论前列消癌汤治疗激素前列腺癌疗效显著,明显降... 更多

【关键词】前列消癥汤;激素前列腺癌;临床疗效观察;

【所属期刊栏目】 经验交流 (2016年02期)

一、资料与方法

1. 一般资料: 选取我院 2012 年 1 月至 2014 年 11 月收纳 的98例激素前列腺癌患者,按随机分配原则分为观察组和对 照组,各49例,观察组49例中,男26例,女23例,年龄39~ 69 岁,平均(48.3±6.4)岁;对照组49 例,男21 例,女28 例, 年龄 33~63 岁, 平均(47.8±6.9)岁; 观察组及对照组在常规 检查后基本一般资料如年龄、性别、血脂、血糖、文化程度、入 院时临床资料等方面具有可比性,差别不大,无统计学意义 (P>0.05)。本研究经本院伦理委员会批准,所有受试者均 签署知情同意书,研究人员合格通过医院研究内容培训考核。 纳入标准14 : 纳入研究患者均由病理检查等原因确诊为激 素前列腺癌患者:排除短期内并发急慢性感染、患有严重心肺 基础性疾病的患者。入院近3个月内未并发急慢性感染,未 使用抗血小板药物,无出血或输血史。排除入院时伴有循环

者临床疗效,在两组治疗过后采取 SAS 焦虑量表、生活质量 自评量表对患者生存质量及心理状态的变化进行评估分析。 疗效判定标准[]:①无效:患者排尿困难,尿频尿急尿痛,骨 盆疼痛,咳嗽,下肢水肿,乏力,厌食等临床症状,体征无改善 迹象,无明显变化,血清前列腺特异性抗原明显增高,症状恶 化。②有效:患者排尿困难,尿频尿急尿痛,骨盆疼痛,咳嗽, 下肢水肿,乏力,厌食等临床症状,体征部分改善或者缓解,但 未完全消失,血清前列腺特异性抗原有所增高,但不多;③显 效:患者临床症状,体征明显改善,血清前列腺特异性抗原不 变或略微增高。

3. 统计学方法: 定量资料由不同数据类型洗取对应的 (检验,表格数据以均数 \pm 标准差($\bar{x} \pm s$)表示;定性资料采用 χ^2 检验。采用 SPSS 17.0 统计软件进行统计分析,按 α = 0.05的检验水准,以P<0.05 为有统计学意义。

2016 China Academic Journal Electronic Publishing House. All rights reserved. http://www.cnki.net

· 172 ·

齐齐哈尔医学院学报 2016 年第 37 卷第 2 期 Journal of Qiqihar University of Medicine, 2016, Vol. 37, No. 2

二、结果

1. 两组患者进行治疗后生存质量评分对比: 两组患者讲

具有统计学意义(P<0.05)。观察组及为:...组激素前列服癌 里者总有效率分别为95.9%、7.5%、观察组总有效率比对照

下一研究宫颈癌的文章, 就会有男性对照组?

小结

■ 选刊:知己知彼,百战不殆

■ 写作: 己所不欲, 勿施于人

■ 投稿: 博学之, 审问之, 慎思之, 明辨之, 笃行之

谢!